(Q37111857)

18 August 2017

1 reference

title

New strategies for the treatment of hyperparathyroidism incorporating calcimimetics (English)

1 reference

18 August 2017

1 reference

Angel L M de Francisco

series ordinal

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

795-811

1 reference

The diagnosis and management of asymptomatic primary hyperparathyroidism

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Recent developments in the management of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Calcium receptor and regulation of parathyroid hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Calcimimetics with potent and selective activity on the parathyroid calcium receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Overexpression of mutated Cu,Zn-SOD in neuroblastoma cells results in cytoskeletal change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Parathyroid hormone gene expression in hypophosphatemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Pathophysiology and recent advances in the management of renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Phosphate regulation of vascular smooth muscle cell calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Vitamin D treatment in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

FGF-23 in patients with end-stage renal disease on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Aluminium and bone disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Bile acid binding to sevelamer HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Novel dosage forms and regimens for sevelamer-based phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Progressive accumulation of lanthanum in the liver of normal and uremic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Achieving therapeutic targets in the treatment of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Hyperparathyroidism and long-term bone loss after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Recent Advances in the Management of Primary Hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.5.795

21 January 2018

Identifiers

DOI

10.1517/14656566.9.5.795

1 reference

18 August 2017

1 reference